STOCK TITAN

Perrigo Co Plc SEC Filings

PRGO NYSE

Welcome to our dedicated page for Perrigo Co Plc SEC filings (Ticker: PRGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The Perrigo Company plc (NYSE: PRGO) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other key documents filed with the Securities and Exchange Commission. Perrigo is incorporated in Ireland and files its reports as a foreign private issuer with ordinary shares listed on the New York Stock Exchange under the symbol PRGO.

Through its Form 8-K filings, Perrigo reports material events such as quarterly earnings releases, strategic reviews and significant transactions. Recent 8-Ks have furnished earnings results for its Consumer Self-Care Americas and Consumer Self-Care International segments, described non-GAAP measures such as adjusted operating income, adjusted diluted earnings per share, organic net sales and constant currency net sales, and outlined the items excluded in these non-GAAP metrics, including amortization of acquired intangibles, restructuring charges, unusual litigation, impairment charges, divestiture gains or losses and infant formula remediation.

Other 8-K filings detail corporate actions such as the entry into a Master Sale and Purchase Agreement to sell Perrigo’s Dermacosmetics branded business in Northern Europe, the Netherlands and Poland, and executive leadership changes and related compensation arrangements. These filings provide insight into how the company is managing its portfolio, capital allocation and organizational structure.

On Stock Titan, users can view Perrigo’s filings as they are made available from EDGAR and use AI-powered summaries to understand the main points of lengthy documents. This includes context around earnings-related disclosures, explanations of non-GAAP reconciliations and highlights from transaction agreements and governance updates. For investors tracking PRGO, this page serves as a centralized view of Perrigo’s regulatory reporting history and ongoing disclosure practices.

Rhea-AI Summary

Perrigo Company plc executive Abigail Lennox, EVP and CSO, reported equity transactions on February 6, 2026. She exercised 3,185 Restricted Stock Units, converting them into the same number of ordinary shares at $14.64 per share. To cover tax obligations, 1,660 ordinary shares were withheld at $14.64. Following these transactions, she directly holds 2,780 ordinary shares and 6,368 Restricted Stock Units, each RSU representing a contingent right to receive one ordinary share, vesting in three equal annual installments beginning February 6, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Neuberger Berman Group LLC and Neuberger Berman Investment Advisers LLC report beneficial ownership of 7,535,309 Perrigo Co PLC common shares, representing 5.5% of the class. All voting and dispositive authority over these shares is shared, with no sole power reported. The firms state the holdings are managed in various fiduciary accounts where Perrigo shares are owned economically by underlying clients. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Perrigo.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
ownership
-
Rhea-AI Summary

BlackRock, Inc. filed an amended beneficial ownership report on Perrigo Company plc, stating that its reporting business units beneficially own 15,941,915 shares of Perrigo common stock, equal to 11.6 % of the class as of the reported date. BlackRock reports sole voting power over 15,479,279 shares and sole dispositive power over 15,941,915 shares, with no shared voting or dispositive power. The filing notes that one holder, iShares Core S&P Small-Cap ETF, has an interest in more than five percent of Perrigo’s outstanding common stock. BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Perrigo.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Perrigo Company plc reported an insider equity award to one of its directors. On December 12, 2025, the director acquired 2,140 restricted stock units, each representing a contingent right to receive one ordinary share.

The restricted stock units are scheduled to vest on December 12, 2026. Following this grant, the director beneficially owns 41,160.148 ordinary shares on a direct basis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Perrigo Company plc director Geoffrey Parker reported an equity award and his updated holdings in the company’s ordinary shares. On 12/12/2025, he received 2,140 Restricted Stock Units, each representing a contingent right to receive one Perrigo ordinary share, scheduled to vest on 12 December 2026.

After this award, he beneficially owns 28,912 ordinary shares directly, 25,879 ordinary shares through a revocable trust, 17,375 ordinary shares in a Roth IRA, and 2,140 Restricted Stock Units as a derivative security position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Perrigo (PRGO): T. Rowe Price Associates, Inc. filed Amendment No. 3 to Schedule 13G reporting beneficial ownership of 16,920,302 shares of common stock, representing 12.3% of the class as of 09/30/2025.

The filer reports sole voting power over 16,856,660 shares and sole dispositive power over 16,920,302 shares, with no shared voting or dispositive power. T. Rowe Price files as an investment adviser and states the securities were acquired and are held in the ordinary course, not to change or influence control.

Within the reported holdings, T. Rowe Price Mid-Cap Value Fund has an interest in 9,190,014 shares, equal to 6.7% of the class.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Perrigo Co plc (PRGO) reported an insider transaction by director Geoffrey Parker. On 11/12/2025, Parker purchased 7,500 ordinary shares at a weighted average price of $14.18 per share, executed in multiple trades ranging from $14.16 to $14.20. The shares were acquired indirectly via a Roth IRA.

Following the transaction, Parker beneficially owned 17,375 shares indirectly (IRA), 28,912 shares directly, and 25,879 shares indirectly through a revocable trust where he and Jill Parker serve as trustees.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Perrigo Company plc reported third-quarter 2025 results. Net sales were $1,043.3 million versus $1,087.5 million a year ago, while operating income was $72.6 million versus $80.4 million. Net income was $7.5 million compared with a loss of $21.0 million in the prior-year quarter. Interest expense improved to $40.6 million from $57.6 million.

Year to date, sales were $3,143.5 million versus $3,235.1 million, with operating income of $164.9 million (versus a slight loss last year) and a net loss of $7.3 million (versus $127.3 million). Cash from operating activities was $63.1 million. Cash stood at $432.1 million and long‑term debt at $3,608.1 million. Inventories were $1,227.0 million.

The company agreed to sell its Dermacosmetics branded business for up to €327 million, including €300 million upfront and up to €27 million in earn‑outs, subject to regulatory and works council approvals, with closing expected in the first quarter of 2026. Related assets and liabilities held for sale were $280.5 million and $37.4 million, respectively. Shares outstanding were 137,624,009 as of October 31, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.21%
Tags
quarterly report
-
Rhea-AI Summary

Perrigo Company plc (PRGO) furnished an 8-K announcing two items: it released earnings for the third quarter ended September 27, 2025 (Item 2.02), and it is initiating a strategic review of its infant formula business (Item 7.01). Both related press releases were furnished as Exhibits 99.1 and 99.2 on November 5, 2025.

The company highlighted use of non-GAAP measures to evaluate ongoing operating trends, comparability, and performance assessment. For recent periods, adjustments included amortization of acquired intangibles, unusual litigation, restructuring and termination benefits, impairment charges, infant formula remediation, divestiture gains or losses, foreign currency translation, non-GAAP tax adjustments, and other items. Management also references constant currency net sales and free cash flow among the metrics it reviews.

The earnings and strategic review press releases are expressly furnished, not filed, limiting their incorporation by reference under the Exchange Act and Securities Act.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.21%
Tags
current report
Rhea-AI Summary

Perrigo Company plc (PRGO) reporting person Matthew John Winterman received grants of restricted stock units on 07/08/2025 totaling 36,846 units: 31,319 RSUs and 5,527 RSUs. Each RSU represents a contingent right to receive one ordinary share. The filing shows no prior beneficial ownership before these reported transactions and records direct ownership of the 31,319 and 5,527 ordinary shares following the awards. The 31,319 RSUs include a vesting provision noted in the filing as vesting in two equal annual installments beginning July 8, 2026, while the 5,527 RSUs vest in three equal annual installments beginning July 8, 2026. The form is signed by an attorney-in-fact for Mr. Winterman and was filed on 08/22/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Perrigo Co Plc (PRGO)?

The current stock price of Perrigo Co Plc (PRGO) is $14.38 as of February 12, 2026.

What is the market cap of Perrigo Co Plc (PRGO)?

The market cap of Perrigo Co Plc (PRGO) is approximately 2.0B.
Perrigo Co Plc

NYSE:PRGO

PRGO Rankings

PRGO Stock Data

2.01B
137.02M
0.41%
105.88%
5.38%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Ireland
DUBLIN 2

PRGO RSS Feed